1.
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
by Scheen, André J
The Lancet (British edition), 2006, Vol.368 (9548), p.1660-1672
2.
Multisystemic Therapy Compared to Telephone Support for Youth with Poorly Controlled Diabetes: Findings from a Randomized Controlled Trial
by Ellis, Deborah A
Annals of behavioral medicine, 2012-05-30, Vol.44 (2), p.207-215
3.
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
by Ahrén, Bo
The journal of clinical endocrinology and metabolism, 2004-05, Vol.89 (5), p.2078-2084
4.
A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes
by Niewczas, Monika A
Nature medicine, 2019-05, Vol.25 (5), p.805-813
5.
Qualitative Evaluation of a Mobile Phone and Web-Based Collaborative Care Intervention for Patients with Type 2 Diabetes
by Lyles, Courtney Rees
Diabetes technology & therapeutics, 2011-05-01, Vol.13 (5), p.563-569
6.
Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline
by Peters, Anne L
The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.3922-3937
7.
Using human genetics to understand the disease impacts of testosterone in men and women
by Ruth, Katherine S
Nature medicine, 2020-02, Vol.26 (2), p.252-258
8.
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
by Kearney, P M
The Lancet (British edition), 2008, Vol.371 (9607), p.117-125
9.
Lower circulating irisin is associated with type 2 diabetes mellitus
by Liu, Jian-Jun
Journal of diabetes and its complications, 2013, Vol.27 (4), p.365-369
10.
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
by Schernthaner, Guntram
Diabetologia, 2018-02-07, Vol.61 (7), p.1503-1516
11.
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
by Thomas, Merlin C
Diabetologia, 2018-08-22, Vol.61 (10), p.2098-2107
12.
Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose
by Merino, Jordi
Diabetologia, 2018-04-06, Vol.61 (6), p.1315-1324
13.
Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes: case-cohort study within the PREDIMED Trial
by Ruiz-Canela, Miguel
Diabetologia, 2018-04-16, Vol.61 (7), p.1560-1571
14.
Pathophysiology of diabetic dyslipidaemia: where are we?
by Verges, Bruno
Diabetologia, 2015-03-01, Vol.58 (5), p.886-899
15.
Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011
by Huo, Lili
Diabetologia, 2018-02-22, Vol.61 (5), p.1055-1063
16.
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
by Ray, Kausik K, Dr
The Lancet (British edition), 2009, Vol.373 (9677), p.1765-1772
17.
Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration
by UK Hypoglycaemia Study Group
Diabetologia, 2007, Vol.50 (6), p.1140-1147
18.
Associations of objectively measured sedentary behaviour and physical activity with markers of cardiometabolic health
by Henson, J
Diabetologia, 2013-03-01, Vol.56 (5), p.1012-1020
19.
The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes
by Khan, Saifur R
Diabetologia, 2019-01-15, Vol.62 (4), p.687-703
20.
Racial and Ethnic Differences in the Relationship between HbA1c and Blood Glucose: Implications for the Diagnosis of Diabetes
by Herman, William H
The journal of clinical endocrinology and metabolism, 2012-04, Vol.97 (4), p.1067-1072
